Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | TOP2A | P11388 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | CES1 | P23141 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | NT5E | P21589 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 5/20 | 0.72 |
| ▸ | ALB | P02768 | 3/20 | 0.72 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.72 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | GLI1 | P08151 | 1/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.72 |
| ▸ | DPP4 | P27487 | 1/20 | 0.72 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.72 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lupeol SCHEMBL14067725 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL148519 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL18100186 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL17036708 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL561024 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL7742344 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL148518 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL21927816 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL21847985 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES | |
| Lupeol SCHEMBL15263404 | 1.00 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281702-A1 | METHOD OF ISOLATING ANTI-VIRAL INGREDIENTS FROM BAPHICACANTHUS CUSIA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2017-10-05 | — | — | US | disclosed |
| US-20170281702-A1 | METHOD OF ISOLATING ANTI-VIRAL INGREDIENTS FROM BAPHICACANTHUS CUSIA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2017-10-05 | — | — | US | disclosed |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | BIONICHE ANIMAL HEALTH USA, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8747815-B2 | Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins | LABORATOIRES EXPANSCIENCE (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8747815-B2 | Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins | LABORATOIRES EXPANSCIENCE (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8551496-B2 | Boswellia low polar gum resin extract and its synergistic compositions | LAILA NUTRACEUTICALS (IN) | 2013-10-08 | — | — | US | disclosed |
| US-20130084348-A1 | COMPOSITIONS COMPRISING NON-ACIDIC BOSWELLIA OIL FRACTION AS A BIO-ENHANCER FOR ENHANCING BIOAVAILABILITY OF BIOLOGICAL AGENTS | LAILA NUTRACEUTICALS (IN) | 2013-04-04 | — | — | US | disclosed |
| EP-2088152-B1 | N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | INST NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) | 2012-02-01 | — | — | EP | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | INSTITUT NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) | 2010-04-08 | — | — | US | disclosed |
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (US) | 2009-09-03 | — | — | US | disclosed |
| EP-2088152-A1 | N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | Institut Neftekhimii I Kataliza Rossiiskoi Akademii Nauk (RU) | 2009-08-12 | — | — | EP | disclosed |
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | EBP, PGGT1B, LIPC | PTPN1 3600/4885TOP2A 1470/4885CES2 507/4885 |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | HAVCR2, FURIN, SARS1 | PTPN1 3317/4885TOP2A 3702/4885CES2 71/4885 |
| US-20170281702-A1 | METHOD OF ISOLATING ANTI-VIRAL INGREDIENTS FROM BAPHICACANTHUS CUSIA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE | LSS, UGT1A7, LARP7 | PTPN1 1727/4885TOP2A 353/4885CES2 27/4885 |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | GART, DNPEP, IL4I1 | PTPN1 708/4885TOP2A 3234/4885CES2 1217/4885 |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | NR3C1, NR5A1, NR3C2 | PTPN1 855/4885TOP2A 982/4885CES2 2448/4885 |
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | SOST, BPGM, PTMS | PTPN1 2716/4885TOP2A 3703/4885CES2 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.